Lead Program
Gain’s lead drug candidate GT-02287 is a best-in-class small molecule, for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases. GT-02287 is currently being evaluated in a Phase I clinical study.
OUR DRUG DISCOVERY PLATFORM MAGELLAN™
By leveraging AI-supported 3D structural biology and supercomputer-powered proprietary physics-based models, Gain’s Magellan™ platform is able to identify novel allosteric binding sites on disease-implicated proteins and exploit their untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.
ALLOSTERIC PROTEIN REGULATION
Our next generation allosteric small molecule therapeutics can modulate a protein to restore or disrupt function, not just through inhibition or activation, but also through stabilization, destabilization and degradation, based on disease pathology.
